Partner Research Organizations
SCIENCE AND DRUG DISCOVERY InterX is a biotech company revolutionizing biomolecular computation by applying proprietary tools to the discovery and design of novel therapeutic molecules. We make drug discovery faster, simpler and more accurate. Using principles of Physics, Mathematics, Computer Science, Computational Chemistry and Biology, InterX derives rules of molecular interactions to predict the properties and behaviors of complex systems. Through advanced proprietary software that approximates inherently quantum mechanical processes underlying biochemical interactions, InterX develops novel and reliable means of predicting the real-world outcomes of biophysical processes. Our goal is to achieve accuracy of 0.5 Kcal/Mol in precision of ensemble properties prediction for Ligand binding. Through advanced proprietary software that approximates inherently quantum mechanical processes underlying biochemical interactions, InterX develops novel and reliable means of predicting the real-world outcomes of biophysical processes. InterX operates at the nexus of academic research and pharma-tech industry. We partner with leading edge researchers, drug developers, and biotechnology companies across the globe to predict drug-target interactions using the most advanced computer algorithms available. The InterX Lab Division is applying computational and structural techniques to understanding critical biological problems. Through understanding, we gain insights and control over these processes. Our current focus is on developing new therapies for combating cancer by leveraging our in-depth knowledge of transcriptional regulation with the novel computational and structural methods developed in InterX. InterX Development Division focuses on bridging the risk gap in Drug Discovery from drug targets to novel candidates. The Development Division applies InterX’s proprietary computer-aided drug design platform, while developing collaborations with Research Centers, Pharma companies, Start-ups, Academia and Accelerators. Such collaborations help distill the drug discovery process – from target identification to lead optimization. InterX, led by Nobel Prize-winning scientists, is developing tools for pharmaceutical ligand design, material science, and biochemistry. We leverage our proprietary software tools for internal molecule development work, as well as joint ventures. Over 80% of our staff are PhDs with academic and industry experience. Development Division Advisory Board
BRIDGING THE GAP BETWEEN
See how it works
Research Division
Molecular Simulations That Shape the Future of Computational Science
Collaborative Research & Development
LAB DIVISION
Development Division
About Us
OUR DEDICATED TEAM
Management
JEPHTAH LORCH
CHIEF EXECUTIVE OFFICER
(Israel)
Board of Directors
Scientific and Strategic
